CY1105475T1 - Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων - Google Patents

Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων

Info

Publication number
CY1105475T1
CY1105475T1 CY20061101312T CY061101312T CY1105475T1 CY 1105475 T1 CY1105475 T1 CY 1105475T1 CY 20061101312 T CY20061101312 T CY 20061101312T CY 061101312 T CY061101312 T CY 061101312T CY 1105475 T1 CY1105475 T1 CY 1105475T1
Authority
CY
Cyprus
Prior art keywords
methods
compositions
neoplasms
protein
therapeutic treatment
Prior art date
Application number
CY20061101312T
Other languages
English (en)
Inventor
Mark I. Greene
Donald M. O'rourke
Ramachandran Murali
Byeong-Woo Park
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26758479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105475(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of CY1105475T1 publication Critical patent/CY1105475T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Αποκαλύπτονται μέθοδοι θεραπευτικής αγωγής ατόμου που έχει νεόπλασμα που μεσολαβείται από πρωτεΐνη erbB. Αποκαλύπτονται μέθοδοι αποτροπής νεοπλασμάτων που μεσολαβούνται από πρωτεΐνη erbB. Οι μέθοδοι περιλαμβάνουν την χορήγηση στο άτομο μορίου νουκλεϊκού οξέος που κωδικοποιεί πρωτεΐνη η οποία διμερίζεται με πρωτείνη erbB και η οποία έχει ανεπαρκή δραστικότητα κινάσης τυροσίνης. Αποκαλύπτονται συνθέσεις που περιλαμβάνουν αυτά τα μόρια νουκλεϊκών οξέων, που περιλαμβάνουν και φαρμακευτικές συνθέσεις.
CY20061101312T 1998-03-04 2006-09-14 Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων CY1105475T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7678898P 1998-03-04 1998-03-04
US09/111,681 US6417168B1 (en) 1998-03-04 1998-07-08 Compositions and methods of treating tumors
PCT/US1999/004777 WO1999044645A1 (en) 1998-03-04 1999-03-04 Compositions and methods of treating tumors

Publications (1)

Publication Number Publication Date
CY1105475T1 true CY1105475T1 (el) 2010-04-28

Family

ID=26758479

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101312T CY1105475T1 (el) 1998-03-04 2006-09-14 Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων

Country Status (13)

Country Link
US (8) US6417168B1 (el)
EP (2) EP3034093B1 (el)
JP (2) JP2002505309A (el)
AT (1) ATE334702T1 (el)
AU (1) AU757237C (el)
CA (1) CA2322592A1 (el)
CY (1) CY1105475T1 (el)
DE (1) DE69932600T2 (el)
DK (1) DK1058562T3 (el)
ES (2) ES2270586T3 (el)
HK (1) HK1225997A1 (el)
PT (1) PT1058562E (el)
WO (1) WO1999044645A1 (el)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
CA2222140C (en) 1995-06-15 2010-11-23 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
EP2042194A3 (en) * 1999-05-14 2009-04-22 Imclone Systems, Inc. Treatment of refractory human tumors with epidermal growth factor receptor antagonists
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4579471B2 (ja) * 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
EP1280923A2 (en) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, a human trypsin family member and uses thereof
AU2001295002B2 (en) * 2000-08-09 2007-05-31 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20050239738A1 (en) * 2000-11-17 2005-10-27 Rupert Schmidt-Ullrich Genetic inhibition of epidermal growth factor receptor function and carcinoma cell radiosensitization
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
AU2002257132A1 (en) 2001-04-06 2002-10-21 The Trustees Of The University Of Pennsylvania Erbb interface peptidomimetics and methods of use thereof
JP4414142B2 (ja) 2001-05-11 2010-02-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2003012072A2 (en) * 2001-08-03 2003-02-13 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
WO2003061559A2 (en) * 2001-10-12 2003-07-31 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
MXPA04003514A (es) 2001-10-19 2004-07-23 Vascular Biogenics Ltd Construcciones de polinucleotidos, composiciones farmaceuticas y metodos para reducir la regulacion dirigida de angionesis y terapia anticancer.
AU2002365396A1 (en) * 2001-11-21 2003-06-10 The Trustees Of The University Of Pennsylvania Peptides, peptide compositions,and methods of use in binding p 185
BR0308783A (pt) * 2002-04-25 2005-01-04 Crucell Holland Bv Vetor de adenovìrus recombinante, método para produzir um vetor de adenovìrus recombinante, composição farmacêutica, método para tratar um corpo humano, e, kit de partes
US20030202973A1 (en) * 2002-04-29 2003-10-30 Dr. George Pieczenik Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
EP1513543B1 (en) 2002-05-23 2010-10-06 The Trustees of The University of Pennsylvania Fas peptide mimetics and uses thereof
AU2003249728A1 (en) 2002-07-03 2004-01-23 The Curators Of The University Of Missouri ErbB-2 RECEPTOR TARGETING PEPTIDE
WO2004008099A2 (en) * 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
CA2506320A1 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
EP1613732A4 (en) * 2003-04-01 2012-03-14 Monogram Biosciences Inc INTRA-CELLULAR COMPLEXES AS BIOMARKERS
EP1681983A4 (en) * 2003-10-14 2008-12-10 Monogram Biosciences Inc RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY
JP4734319B2 (ja) * 2004-03-19 2011-07-27 イムクローン・リミテッド・ライアビリティ・カンパニー ヒト抗上皮成長因子受容体抗体
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
US20060188509A1 (en) 2005-02-23 2006-08-24 Genentech, Inc. Extending time to disease progression or survival in cancer patients
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US8465732B2 (en) 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
CN101711284A (zh) 2007-01-25 2010-05-19 达娜-法勃肿瘤研究所 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
EP3248617A3 (en) 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech Inc Predição de resposta a um inibidor de her
MX2009009782A (es) 2007-03-15 2010-09-10 Ludwig Inst Cancer Res Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
CN101827860A (zh) * 2007-10-16 2010-09-08 西福根有限公司 包含最佳化her1和her3多聚体的组合物及其使用方法
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
DK2769991T3 (en) 2008-01-03 2018-12-10 Scripps Research Inst ANTIBODY TARGETING WITH A MODULAR RECOGNITION AREA
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
CN102224255A (zh) 2008-08-15 2011-10-19 梅里麦克制药股份有限公司 用于预测细胞对治疗剂的应答的方法和系统
MX2011004467A (es) * 2008-10-31 2011-07-28 Biogen Idec Inc Moleculas de objetivo light y usos de las mismas.
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
AU2011224186C1 (en) 2010-03-11 2015-04-02 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2575880B1 (en) 2010-05-27 2019-01-16 Genmab A/S Monoclonal antibodies against her2 epitope
CN103154035B (zh) 2010-05-27 2017-05-10 根马布股份公司 针对her2的单克隆抗体
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9427458B2 (en) * 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
AU2012258637B2 (en) 2011-05-24 2017-07-20 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
KR20140096092A (ko) 2011-11-17 2014-08-04 바이엘 메디컬 케어 인크. 의료 진단 절차들에 관한 정보를 수집하고 보고하고 관리하는 방법들 및 기법들
JP6180425B2 (ja) 2011-11-23 2017-08-23 メディミューン，エルエルシー Ｈｅｒ３に特異的な結合分子及びそれらの使用
JP2015500638A (ja) 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
KR102051505B1 (ko) * 2012-02-23 2019-12-03 다이이치 산쿄 유럽 게엠베하 방사선 감수성 조절을 위한 ｈｅｒ３ 억제제
BR112014024017A8 (pt) 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
KR20150131263A (ko) 2013-03-14 2015-11-24 조지타운 유니버시티 신경 작용제에 대한 노출을 위한 치료
EA038918B1 (ru) 2013-03-15 2021-11-09 Зинджения, Инк. Пептид, связывающий рецептор эпидермального фактора роста, мультиспецифические комплексы, содержащие пептид и антитела, и их применение
US11446516B2 (en) 2013-08-09 2022-09-20 The Trustees Of The University Of Pennsylvania Methods of increasing response to cancer radiation therapy
AU2014306322A1 (en) * 2013-08-09 2016-03-17 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with anti-erbB antibody for the treatment of cancers
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
KR102393885B1 (ko) * 2014-06-27 2022-05-02 앤지오크린 바이오사이언스 인코포레이티드 아데노바이러스 e4orf1을 발현하는 신경 세포 및 그 제조 방법과 용도
WO2016168634A1 (en) * 2015-04-17 2016-10-20 Bulldog Pharmaceuticals, Inc. Biomarkers related to treatment of cancer with her3 and egfr inhibitors
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
JP7234149B2 (ja) 2017-07-07 2023-03-07 バイエル・ヘルスケア・エルエルシー 注入システム間でデータをピア交換するためのシステム、方法、及び、コンピュータプログラムプロダクト
WO2019185164A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Her3 antigen-binding molecules
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CN118234752A (zh) * 2021-09-13 2024-06-21 德克萨斯大学系统董事会 Lilrb2特异性单克隆抗体及其使用方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US600377A (en) * 1898-03-08 Spring saddle-post
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
AU583801B2 (en) * 1983-10-26 1989-05-11 Sheldon B. Greer Method and materials for sensitizing neoplastic tissue to radiation
US5637677A (en) * 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
US5200178A (en) 1988-02-26 1993-04-06 The General Hospital Corporation Method for tumor detection
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5705157A (en) 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
JPH0776238B2 (ja) 1990-04-06 1995-08-16 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ｎｅｕ遺伝子産物のためのリガンド
US5367060A (en) 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
WO1993014781A1 (en) 1992-01-24 1993-08-05 The Regents Of The University Of California Novel peptides and method for altering the activity of allosteric proteins
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69326937T2 (de) 1993-03-24 2000-12-28 Berlex Biosciences, Richmond Kombination von Antihormonale und bindende Moleküle zur Krebsbehandlung
AU6527894A (en) * 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
US6733752B1 (en) * 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US5837523A (en) 1994-05-05 1998-11-17 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6100377A (en) 1994-06-10 2000-08-08 The Trustees Of The University Of Pennsylvania Constrained peptides
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
EP0740187B1 (en) 1995-04-28 2004-06-23 Hewlett-Packard Company, A Delaware Corporation Electro-optic display
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6281010B1 (en) 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
CA2246429C (en) * 1996-03-27 2007-07-24 Genentech, Inc. Erbb3 antibodies
BR9710357A (pt) 1996-07-12 1999-08-17 Genentech Inc Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo
AU4982097A (en) 1996-10-18 1998-05-15 Board Of Regents, The University Of Texas System Anti-erbb2 antibodies
US6074640A (en) * 1997-10-30 2000-06-13 Uab Research Foundation Enhancement of tumor cell radiosensitivity using single chain intracellular antibodies
WO1998018489A1 (en) 1996-10-30 1998-05-07 The Uab Research Foundation Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
US6027892A (en) * 1996-12-30 2000-02-22 Chang Esther H Compositions and methods for reducing radiation and drug resistance in cells
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
EP1745799B1 (en) 1998-03-04 2015-09-02 The Trustees of The University of Pennsylvania Compositions and methods of treating tumors
AU4079999A (en) 1998-05-15 1999-12-06 Imclone Systems Incorporated Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
DE10124566A1 (de) 2001-05-15 2002-11-21 Zeiss Carl Optisches Abbildungssystem mit Polarisationsmitteln und Quarzkristallplatte hierfür
US6828474B2 (en) 2002-03-06 2004-12-07 National Starch & Chemical Investment Holding Corporation Method of grain production for heterozygous waxy sugary-2 maize
WO2010129579A2 (en) 2009-05-05 2010-11-11 Florida Renewable Energy Corporation Fluid-based power generation system
DK2686017T3 (da) 2011-03-14 2019-10-07 Drug Delivery Solutions Ltd Oftalmisk sammensætning
US9507157B2 (en) 2014-12-17 2016-11-29 Zhen Tang Size-adjustable elliptical laser marker
TWI713998B (zh) 2019-02-22 2020-12-21 南亞塑膠工業股份有限公司 一種含二氧化鈦漿料的製作及應用於回收聚酯纖維

Also Published As

Publication number Publication date
US20020165193A1 (en) 2002-11-07
EP3034093B1 (en) 2019-03-13
AU757237B2 (en) 2003-02-06
ES2270586T3 (es) 2007-04-01
DE69932600T2 (de) 2007-08-09
EP3034093A1 (en) 2016-06-22
AU757237C (en) 2004-03-18
JP2012017341A (ja) 2012-01-26
US20160083478A1 (en) 2016-03-24
US20160289334A2 (en) 2016-10-06
EP1058562B1 (en) 2006-08-02
JP2002505309A (ja) 2002-02-19
ES2551932T3 (es) 2015-11-24
EP1058562A1 (en) 2000-12-13
JP5719270B2 (ja) 2015-05-13
US20130204069A1 (en) 2013-08-08
DK1058562T3 (da) 2006-11-13
US6417168B1 (en) 2002-07-09
US20090010935A1 (en) 2009-01-08
US20170355778A1 (en) 2017-12-14
WO1999044645A1 (en) 1999-09-10
ATE334702T1 (de) 2006-08-15
CA2322592A1 (en) 1999-09-10
US20120014965A1 (en) 2012-01-19
PT1058562E (pt) 2006-11-30
US7625558B2 (en) 2009-12-01
HK1225997A1 (zh) 2017-09-22
US20150010551A1 (en) 2015-01-08
DE69932600D1 (de) 2006-09-14
EP1058562A4 (en) 2003-02-05
AU2802199A (en) 1999-09-20

Similar Documents

Publication Publication Date Title
CY1105475T1 (el) Συνθεσεις και μεθοδοι θepαπευτικης αγωγης νεοπλασματων
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
CY1118363T1 (el) Αντισωματα που ανοσοειδικως συνδεονται προς blys
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
DE69912151D1 (de) Carbonsäuren und carbonsäureisostere von n-heterocyclischen verbindungen
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
CY1111120T1 (el) Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση
CY1105501T1 (el) Συνδυασμοι φαρμακων (π.χ. chlorpromazine και pentamidine) για την αντιμετωπιση νεοπλαστικων διαταραχων
CY1106601T1 (el) Χρηση του παραγωγου κουιναζολινης zd6474 συνδυασμενου με γκεμσιταμπινη και προαιρετικα με ιοντιζουσα ακτινοβολια στη θεραπεια του καρκινου
CY1109340T1 (el) Μεθοδοι θεραπειας bcl-2 διαταραχης χρησιμοποιωντας bcl-2 αντιπληροφοριακα ολιγομερη
DE69633725D1 (de) Kationische lipide/dns komplexe zum zielen von genen
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
FI940375A (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE293695T1 (de) Humanes akt-3 protein
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
ATE267611T1 (de) MENSCHLICHES ßMINOR VAULTß PROTEIN P193
DK0811068T3 (da) Humane DNase I varianter
CY1114326T1 (el) Χρηση της λεπτινης για τη θεραπεια της ανθρωπινης λιποατροφιας και μεθοδος καθορισμου της προδιαθεσης στην εν λογω θεραπευτικη αγωγη
DE60235085D1 (de) Herstellungsverfahren von derivate von bisphosphonaten
JP2002348254A5 (el)